Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin injection schedule optimization in wet age-related macular degeneration
NL-OMON27535Active, not recruiting
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of bevacizumab in exudative macular degeneration (2 arms), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoints: Visual acuity at 6 months, Visual acuity at 12 months and 2 more. Started Feb 2008; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON27535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27535.